Tag: Stockholders

Tortoise Acquisition Corp. Announces Approval of Business Combination and Adjourns Special Meeting of Stockholders to September 30, 2020

NEW YORK–(BUSINESS WIRE)–Tortoise Acquisition Corp. (NYSE: SHLL) (“TortoiseCorp”) today announced that its stockholders voted to approve the proposed business combination between TortoiseCorp and Hyliion Inc. (“Hyliion”) and certain related proposals and that it has adjourned its virtual Special Meeting of Stockholders to September 30, 2020 at 1:00 p.m., Eastern time (the “Special Meeting”) to provide its shareholders additional time to vote on one of the ancillary proposals described in TortoiseCorp’s definitive proxy statement, dated September 8, 2020 (the “Proxy Statement”). To attend the reconvened virtual meeting, please visit https://www.cstproxy.com/tortoiseacquisitioncorp/sm2020.

TortoiseCorp urges its stockholders who have not voted to do so as soon as possible. TortoiseCorp received overwhelming support from stockholders for the proposed business combination with Hyliion. A sufficient number of votes to approve the business combination were received and TortoiseCorp expects to close the transaction on Thursday, October 1, 2020. However, TortoiseCorp values the input of all

Read More

Tortoise Acquisition Corp. Reminds Stockholders to Vote in Favor of Business Combination with Hyliion Inc.

Tortoise Acquisition Corp. (NYSE: SHLL) (“TortoiseCorp”) reminds stockholders to vote in favor of the proposed business combination between TortoiseCorp and Hyliion Inc. (“Hyliion”), and the related proposals, to be voted upon at TortoiseCorp’s Special Meeting of Stockholders scheduled to be held virtually on Monday, September 28, 2020, at 9:30 am Eastern time (the “Special Meeting”), as described in TortoiseCorp’s definitive proxy statement, dated September 8, 2020 (the “Proxy Statement”).

Every stockholder’s vote is important, regardless of the number of shares the stockholder holds. Accordingly, TortoiseCorp requests that each stockholder complete, sign, date and return a proxy card, if it has not already done so, to ensure that such stockholder’s shares will be represented at the Special Meeting. Stockholders which hold shares in “street name,” meaning that their shares are held of record by a broker, bank or other nominee, should contact their broker, bank or nominee to ensure that their

Read More

Titan Pharmaceuticals’ Stockholders Approve Proposal To Amend Its Certificate Of Incorporation

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced that, at today’s special meeting, its stockholders approved the proposal to amend Titan’s certificate of incorporation to increase the number of authorized shares of common stock from 125 million to 225 million (the “Amendment”).

The voting results are available in our Current Report on Form 8-K filed with the SEC today.

“On behalf of the Board and management team, I would like to thank our stockholders for their continued support and we look forward to updating you on our progress,” said Titan’s Executive Chairman, Dr. Marc Rubin.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The Company’s lead product is Probuphine® (buprenorphine) implant, a novel

Read More

Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today provided an update on the upcoming special meeting of stockholders (the “Meeting”) in response to recent stockholder inquiries regarding the number of meeting adjournments. The sole purpose of the Meeting is to seek approval of a proposal to amend Titan’s certificate of incorporation to increase the number of authorized shares of common stock.

Without approval of the share increase, the several strategic alternatives management has been exploring with the Company’s bankers will not be possible. The failure to obtain stockholder approval will almost certainly result in the cessation of Titan’s operations and likely a total loss of value to stockholders, given the pledge of all of the Company’s assets as security for its outstanding debt.

The goal of Titan’s Board of Directors is to enable as many stockholders as possible

Read More